<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00686985</url>
  </required_header>
  <id_info>
    <org_study_id>DOCAR study</org_study_id>
    <nct_id>NCT00686985</nct_id>
  </id_info>
  <brief_title>Docetaxel - Carboplatin as Second Line Treatment in Patients With Small Cell Lung Cancer</brief_title>
  <acronym>DOCAR</acronym>
  <official_title>A Phase II Study of Docetaxel - Carboplatin as Second Line Treatment in Patients With Refractory or Relapsed Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeroen Bosch Ziekenhuis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jeroen Bosch Ziekenhuis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II studies with docetaxel in first line - and second line treatment of SCLC&#xD;
      demonstrated that docetaxel is an active agent in these patient groups. Therefore docetaxel&#xD;
      seems suitable for evaluation in combination with other cytotoxic drugs active in this&#xD;
      disease. A phase II study in previously untreated patients with SCLC shows that the&#xD;
      combination docetaxel and cisplatin/carboplatin is an active and well tolerated regimen in&#xD;
      extensive SCLC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      Small cell lung cancer (SCLC) is diagnosed in approximately 15 % of all the lung cancer&#xD;
      cases. SCLC is recognized by its rapid tumor growth, with a high chemo- and radio&#xD;
      sensitivity, and by its high metastasizing potential. Patients with extensive-stage disease&#xD;
      have a 5-year survival rate of 1% to 2%.&#xD;
&#xD;
      Almost 2/3 of the patients have already extensive disease (ED) upon diagnosis.The recommended&#xD;
      treatment of ED-SCLC is systemic chemotherapy, considered to be the standard first line&#xD;
      treatment option in all patients with SCLC regardless of performance status and age.&#xD;
      World-wide, the most commonly used regimen for 1st line treatment is the combination of&#xD;
      cisplatin-etoposide, while in the Netherlands the cyclophosphamide, doxorubicin and etoposide&#xD;
      regimen is widely used.Survival outcome with these regimens appear similar.&#xD;
&#xD;
      Unfortunately, relapses occur in all patients and responses to second-line chemotherapy have&#xD;
      proven to be of short term. Until recently, there were no registered drugs for treatment of&#xD;
      relapsing SCLC. Phase II studies with docetaxel in first line - and second line treatment of&#xD;
      SCLC demonstrated that docetaxel is an active agent in these patient groups. Therefore&#xD;
      docetaxel seems suitable for evaluation in combination with other cytotoxic drugs active in&#xD;
      this disease. Until now no studies have been performed with a combination of docetaxel and&#xD;
      platinum in this group of previously treated SCLC patients.&#xD;
&#xD;
      A phase II study in previously untreated patients with SCLC shows that the combination&#xD;
      docetaxel and cisplatin/carboplatin is an active and well tolerated regimen in extensive&#xD;
      SCLC.&#xD;
&#xD;
      Study objectives:&#xD;
&#xD;
      To evaluate the anti-tumor activity of a docetaxel/carboplatin regimen in patients with&#xD;
      refractory or relapsed SCLC. Furthermore to asses the safety profile of the&#xD;
      docetaxel/carboplatin combination.&#xD;
&#xD;
      Trial design:&#xD;
&#xD;
      This study will be a open label non-randomized study conducted in patients with refractory or&#xD;
      relapsed SCLC. It is a phase II study with 50 patients.&#xD;
&#xD;
      Docetaxel infusion 75 mg/m2, carboplatin AUC = 6 mg/ml·min day 1, every 21 days for 4-6&#xD;
      cycles.&#xD;
&#xD;
      Population:&#xD;
&#xD;
      Patients with histologically or cytologically proven SCLC at the first diagnosis with&#xD;
      refractory or relapsed SCLC after first line treatment. Signed informed consent. Age &gt; 18&#xD;
      years. WHO ps 0,1 or 2.&#xD;
&#xD;
      Endpoints:&#xD;
&#xD;
      Primary endpoint: response rate. Secondary endpoint(s): time to progression, response&#xD;
      duration, safety profile and survival.&#xD;
&#xD;
      Stress and risks for the patient:&#xD;
&#xD;
      Hospital visits and tests are not different from the standard treatment. Stress due to&#xD;
      adverse events is not essential higher estimated. Special risks are not expected. Frequently&#xD;
      medical examination and control of laboratory results will be done. Detailed instruction will&#xD;
      be given about what do to in case of serious toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2007</start_date>
  <completion_date type="Anticipated">July 2010</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>2 yrs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression; Response duration; Survival; Safety profile</measure>
    <time_frame>2 yrs</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin, docetaxel</intervention_name>
    <description>Carboplatin AUC 5, Docetaxel 75 mg/m2, q 3 weeks, 4-6 cycles, 12-18 weeks</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically proven SCLC at the first diagnosis&#xD;
&#xD;
          -  Refractory or relapsed SCLC&#xD;
&#xD;
          -  Measurable disease according to RECIST criteria&#xD;
&#xD;
          -  There must be a minimum of 2 weeks between the end of prior radiotherapy and study&#xD;
             entry. (No more than 30% of available bone marrow should have been irradiated as&#xD;
             recommended by the RTOG).&#xD;
&#xD;
          -  Patients must have fully recovered from toxic effects of previous antitumor therapy.&#xD;
&#xD;
          -  Age &gt; 18 years.&#xD;
&#xD;
          -  WHO performance status 0- 2 (Appendix II).&#xD;
&#xD;
          -  Hb &gt; 6.0 mmol/L,&#xD;
&#xD;
               -  Neutrophils &gt; 1.5 x 109/L,&#xD;
&#xD;
               -  Platelets &gt; 100 x 109/L·&#xD;
&#xD;
          -  Total bilirubin &lt; the upper-normal limits of the institutional normal values.&#xD;
&#xD;
          -  ALAT (SGPT), ASAT (SGOT) &lt; 2.5 times the upper-normal limits of the institutional&#xD;
             normal values.&#xD;
&#xD;
          -  Alkaline Phosphatase &lt; 5 times the upper-normal limits of the institutional normal&#xD;
             values. If AP &gt; 2.5 x ULN then ALAT and ASAT must be &lt;1.5 x ULN, otherwise, the&#xD;
             patient is not eligible&#xD;
&#xD;
          -  Creatinine &lt; 140 mmol/L; or creatinine clearance according to Cockcroft formula &gt;50&#xD;
             ml/min·&#xD;
&#xD;
          -  Signed informed consent prior to beginning protocol specific procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  More than one line of chemotherapy for metastatic disease&#xD;
&#xD;
          -  Treatment with a platinum compound during the last 3 months before randomisation&#xD;
&#xD;
          -  Pregnant or lactating women or women of childbearing potential not adhering to&#xD;
             adequate anticonceptive measures&#xD;
&#xD;
          -  Evidence of (other) active invasive malignancy other than non-melanoma skin cancer.&#xD;
&#xD;
          -  Clinical evidence CNS metastases.&#xD;
&#xD;
          -  Symptomatic peripheral neuropathy &gt; grade 2 according (NCI CTC, Appendix III)Definite&#xD;
             contraindications for the use of corticosteroids&#xD;
&#xD;
          -  Concurrent treatment with other experimental drugs.&#xD;
&#xD;
          -  Participation in another clinical trial with any investigational drug within 30 days&#xD;
             prior to study screening.&#xD;
&#xD;
          -  Concurrent treatment with any other cytotoxic anti-cancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>B Biesma, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jeroen Bosch Ziekenhuis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>B Biesma, Dr.</last_name>
    <phone>31-073-699-2615</phone>
    <email>b.biesma@jbz.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>F.M.N.H. Schramel, Dr.</last_name>
    <phone>31-030-609-3459</phone>
    <email>f.schramel@antonius.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>B. Biesma</name>
      <address>
        <city>'s-Hertogenbosch</city>
        <state>Brabant</state>
        <zip>5211NL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>B. Biesma, Dr.</last_name>
      <phone>31-073-699-2615</phone>
      <email>b.biesma@jbz.nl</email>
    </contact>
    <contact_backup>
      <last_name>F. Schramel, Dr.</last_name>
      <phone>31-0609-9111</phone>
      <email>f.schramel@antonius.net</email>
    </contact_backup>
    <investigator>
      <last_name>H van der Heijden, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>J.N.H. Timmer - Bonte, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>H Smit, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>H.J.M. Groen, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <study_first_submitted>May 27, 2008</study_first_submitted>
  <study_first_submitted_qc>May 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2008</study_first_posted>
  <last_update_submitted>May 29, 2008</last_update_submitted>
  <last_update_submitted_qc>May 29, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. B. Biesma</name_title>
    <organization>Jeroen Bosch Ziekenhuis</organization>
  </responsible_party>
  <keyword>Docetaxel</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>relapse SCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

